Total Payments
$147,455
2024 Payments
$1,336
Companies
24
Transactions
539
Medicare Patients
626
Medicare Billing
$4.9M
Payment Breakdown by Category
Other$102,852 (69.8%)
Consulting$27,408 (18.6%)
Food & Beverage$10,321 (7.0%)
Travel$6,770 (4.6%)
Education$104.00 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $102,852 | 70 | 69.8% |
| Consulting Fee | $27,408 | 12 | 18.6% |
| Food and Beverage | $10,321 | 418 | 7.0% |
| Travel and Lodging | $6,770 | 37 | 4.6% |
| Education | $104.00 | 2 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Biogen, Inc. | $89,268 | 251 | $0 (2024) |
| Mallinckrodt Enterprises LLC | $38,703 | 45 | $0 (2019) |
| Mallinckrodt Hospital Products Inc. | $9,275 | 14 | $0 (2024) |
| Celgene Corporation | $5,794 | 18 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,125 | 62 | $0 (2024) |
| EMD Serono, Inc. | $674.06 | 23 | $0 (2024) |
| Genentech USA, Inc. | $609.18 | 35 | $0 (2024) |
| TG Therapeutics, Inc. | $568.85 | 19 | $0 (2024) |
| Acorda Therapeutics, Inc | $449.31 | 25 | $0 (2020) |
| ANI Pharmaceuticals, Inc. | $216.30 | 10 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,336 | 63 | Novartis Pharmaceuticals Corporation ($344.65) |
| 2023 | $1,847 | 70 | Biogen, Inc. ($439.54) |
| 2022 | $11,595 | 52 | Biogen, Inc. ($10,959) |
| 2021 | $9,291 | 45 | Biogen, Inc. ($9,006) |
| 2020 | $29,872 | 53 | Biogen, Inc. ($20,748) |
| 2019 | $38,540 | 86 | Biogen, Inc. ($18,455) |
| 2018 | $23,634 | 70 | Biogen, Inc. ($15,022) |
| 2017 | $31,340 | 100 | Mallinckrodt LLC ($16,313) |
All Payment Transactions
539 individual payment records from CMS Open Payments — Page 1 of 22
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $22.23 | General |
| Category: Neurology | ||||||
| 12/11/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $21.08 | General |
| Category: Neurology | ||||||
| 12/04/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $31.33 | General |
| Category: IMMUNOLOGY | ||||||
| 11/26/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $21.23 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 11/19/2024 | Genentech USA, Inc. | Ocrevus Zunovo (Biological) | Food and Beverage | In-kind items and services | $15.82 | General |
| Category: Immunology | ||||||
| 11/13/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $18.44 | General |
| Category: Neurology | ||||||
| 11/06/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $25.96 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 10/23/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Food and Beverage | Cash or cash equivalent | $16.32 | General |
| Category: Neurology | ||||||
| 10/16/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $23.40 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 10/07/2024 | Genentech USA, Inc. | Ocrevus Zunovo (Biological) | Food and Beverage | In-kind items and services | $16.58 | General |
| Category: Immunology | ||||||
| 10/02/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $21.08 | General |
| Category: Neurology | ||||||
| 09/26/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $21.48 | General |
| Category: Inflammation/Rare Disease | ||||||
| 09/25/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $23.46 | General |
| Category: Neuroscience | ||||||
| 09/18/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $18.27 | General |
| 09/09/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $11.07 | General |
| Category: Neurology | ||||||
| 09/04/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $21.28 | General |
| Category: Immunology | ||||||
| 08/28/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $20.18 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 08/21/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $18.29 | General |
| Category: Neurology | ||||||
| 08/14/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $31.21 | General |
| 07/31/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $24.57 | General |
| Category: Immunology | ||||||
| 07/23/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $31.04 | General |
| Category: Neurology | ||||||
| 07/17/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $13.30 | General |
| Category: Inflammation/Rare Disease | ||||||
| 07/10/2024 | Genentech USA, Inc. | Ocrevus (Biological) | Food and Beverage | In-kind items and services | $17.32 | General |
| Category: Immunology | ||||||
| 07/08/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $17.90 | General |
| Category: Rare Disease | ||||||
| 07/01/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $18.29 | General |
| Category: Neurology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 179 | 67,608 | $4.4M | $1.3M |
| 2022 | 3 | 118 | 61,511 | $2.8M | $1.2M |
| 2021 | 4 | 138 | 56,988 | $2.6M | $1.1M |
| 2020 | 10 | 191 | 60,415 | $4.1M | $1.3M |
Total Patients
626
Total Services
246,522
Medicare Billing
$4.9M
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J2323 | Injection, natalizumab, 1 mg | Office | 2023 | 28 | 67,200 | $4.3M | $1.3M | 29.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 27 | 217 | $99,390 | $13,411 | 13.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 38 | 44 | $16,813 | $7,115 | 42.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 44 | 59 | $17,561 | $6,221 | 35.4% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 29 | 75 | $5,100 | $2,192 | 43.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 13 | 13 | $9,750 | $2,126 | 21.8% |
| J2323 | Injection, natalizumab, 1 mg | Office | 2022 | 26 | 61,200 | $2.7M | $1.1M | 42.5% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 25 | 202 | $59,580 | $13,626 | 22.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 67 | 109 | $32,482 | $11,865 | 36.5% |
| J2323 | Injection, natalizumab, 1 mg | Office | 2021 | 23 | 56,700 | $2.5M | $1.0M | 41.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 67 | 106 | $31,588 | $12,000 | 38.0% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 26 | 82 | $49,200 | $10,693 | 21.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2021 | 22 | 100 | $21,000 | $7,265 | 34.6% |
| J2323 | Injection, natalizumab, 1 mg | Office | 2020 | 19 | 48,600 | $2.1M | $815,089 | 38.3% |
| J2350 | Injection, ocrelizumab, 1 mg | Office | 2020 | 12 | 11,400 | $1.9M | $493,900 | 26.7% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2020 | 31 | 189 | $113,400 | $25,870 | 22.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 51 | 72 | $20,964 | $6,636 | 31.7% |
| 96415 | Infusion of chemotherapy into a vein | Office | 2020 | 12 | 57 | $7,410 | $1,680 | 22.7% |
| 99354 | Prolonged office or other outpatient service first hour | Office | 2020 | 12 | 13 | $3,536 | $1,580 | 44.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 18 | 20 | $4,360 | $1,105 | 25.3% |
| 96375 | Injection of different drug or substance into a vein for therapy, diagnosis, or prevention | Office | 2020 | 12 | 26 | $1,768 | $414.27 | 23.4% |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 2020 | 12 | 19 | $380.00 | $91.94 | 24.2% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2020 | 12 | 19 | $34.20 | $11.55 | 33.8% |
About Dr. Vincent Macaluso, MD
Dr. Vincent Macaluso, MD is a Neurology healthcare provider based in New Hyde Park, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1700996758.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Vincent Macaluso, MD has received a total of $147,455 in payments from pharmaceutical and medical device companies, with $1,336 received in 2024. These payments were reported across 539 transactions from 24 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($102,852).
As a Medicare-enrolled provider, Macaluso has provided services to 626 Medicare beneficiaries, totaling 246,522 services with total Medicare billing of $4.9M. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location New Hyde Park, NY
- Active Since 08/30/2006
- Last Updated 01/11/2010
- Taxonomy Code 2084N0400X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1700996758
Products in Payments
- TYSABRI (Biological) $73,836
- ACTHAR (Biological) $47,979
- TECFIDERA (Drug) $5,607
- Ozanimod (Drug) $5,568
- KESIMPTA (Drug) $835.21
- BRIUMVI (Drug) $568.85
- AMPYRA (Drug) $429.31
- OCREVUS (Biological) $397.90
- PURIFIED CORTROPHIN GEL (Drug) $308.65
- VUMERITY (Drug) $299.28
- GILENYA (Drug) $267.23
- ZEPOSIA (Drug) $226.13
- MAVENCLAD (Drug) $196.94
- Ocrevus (Biological) $178.88
- ZINBRYTA (Biological) $150.00
- Zinbryta (Biological) $111.32
- UPLIZNA (Drug) $79.26
- UPLIZNA (Biological) $77.91
- AUBAGIO (Drug) $64.19
- UBRELVY (Drug) $53.58
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in New Hyde Park
Vincent Deorchis, M.d, M.D
Neurology — Payments: $38,171
Neurology $38,171
Dr. Michael Nissenbaum
Neurology — Payments: $25,041
Neurology $25,041
Abraham Kalikstein, M.d, M.D
Neurology — Payments: $13,580
Neurology $13,580
Dr. Scott Uretsky, M.d, M.D
Neurology — Payments: $5,620
Neurology $5,620
Dr. Ellen Haddad, Do, DO
Neurology — Payments: $5,548
Neurology $5,548
Arthur Farkash, Md, MD
Neurology — Payments: $3,983
Neurology $3,983